alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › due

due

5 studies tagged due, dated 2010-11-19 to 2023-01-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers 2023-01-01
  2. Sensitivity of Individual and Composite Test Scores from the Cogstate Brief Battery to Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease 2023-01-01
  3. Value of a Panel of 6 Serum Biomarkers to Differentiate Between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease 2020-10-01

Studies

5 studies carry this tag.

Date range

2010 to 2023

Top journals

  • Journal of Alzheimer's disease : JAD 2
  • Alzheimer disease and associated disorders 1
  • Dementia (London, England) 1
  • Neuroscience letters 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Early Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease Using a Composite of MemTrax and Blood Biomarkers

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01 Biomarkers

    Combining MemTrax Memory Test and blood biomarker results is a promising new technique for the early detection of MCI-AD.

  2. Sensitivity of Individual and Composite Test Scores from the Cogstate Brief Battery to Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Journal of Alzheimer's disease : JAD 2023-01-01 Cognitive tests and assessment

    In older adults, the CBB is effective for discriminating cognitive impairment due to MCI or AD-dementia from unimpaired cognition with the LWM composite providing the strongest sensitivity.

  3. Value of a Panel of 6 Serum Biomarkers to Differentiate Between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer disease and associated disorders 2020-10-01 Biomarkers

    This panel of 6 markers in blood serum may indicate underlying neurodegenerative processes in patients with AD at the MCI stage.

  4. A preliminary evaluation of a client-centred prompting tool for supporting everyday activities in individuals with mild to moderate levels of cognitive impairment due to dementia

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Dementia (London, England) 2020-04-04 Cognitive tests and assessment

    The study provides the preliminary evidence that family caregivers can use a touchscreen tablet, software and manual package to identify specific tasks and break these down into steps and that people living with dementia can then follow the prompts to complete the tasks.

  5. Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Neuroscience letters 2010-11-19 Biomarkers

    Familial Alzheimer's disease (AD) due to PSEN1 mutations provides an opportunity to examine AD biomarkers in persons in whom the diagnosis is certain.

All topic tags with their study counts